Cited by 149Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 94 of the 95 references it cites were found in a registry or an index.

Drug development for Alzheimer's disease: Where are we now and where are we headed?

Open access

Sabbagh, Marwan N.·2009·The American journal of geriatric pharmacotherapy

DOI 10.1016/j.amjopharm.2009.06.003PMC PMC2948028

Open this paper in CoChat — free account

Abstract

Objective The aim of this article was to provide a survey of the clinical development of pharmacotherapy for Alzheimer's disease (AD).Methods A search of PubMed to identify pertinent English-language literature was conducted using the terms Alzheimer's disease AND clinical trials (2003-2008), dementia AND prevention AND clinical trials (2003-2008), and the chemical names of all compounds mentioned in articles on new drugs for AD published since 2005. www.ClinicalTrials.gov was searched for relevant trials. Abstracts of the 2008 International Conference on Alzheimer's Disease (ICAD) were reviewed for relevance, as were pharmaceutical company and AD advocacy Web sites. Articles selected for review were primary reports of data from preclinical studies and clinical trials.Results A large number of drugs with differing targets and mechanisms of action are under development for the treatment of AD. Phase III trials of Ginkgo biloba, NSAIDs, phenserine, statins, tarenflurbil, tramiprosate, and xaliproden have been completed, none of them demonstrating adequate efficacy. Encouraging results from completed Phase II trials of dimebon, huperzine A, intravenous immunoglobulin, and methylthioninium chloride were reported at ICAD 2008. Nineteen compounds are currently in Phase II trials, and 3 compounds (AN1792, lecozotan SR, and SGS742) failed at this stage of development.Conclusions Despite disappointing results from recently completed Phase III trials of several novel compounds, the extent and breadth of activity at all phases of clinical development suggest that new pharmacotherapeutic options for the treatment of AD will become available within the next decade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.amjopharm.2009.06.003

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426
Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Decreased Prevalence of Alzheimer Disease Associated With 3-Hydroxy-3-Methyglutaryl Coenzyme A Reductase Inhibitors
Wolozin, B. L. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,408
A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388
Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329

Show all 95 references

Research works printed but not linked: 2

Feldman, 2008, The LEADe study: A randomized controlled trial investigating the effect of atorvastatin on global and cognitive function in patients with mild-to-moderate Alzheimer's disease receiving background therapy of donepezil, Neurology, 71, 154
2007, Xaliproden (Xalprila) for Alzheimer's disease

Sorted by citations

The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization
Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 892
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808
Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C. A., Shankle, W. R., Lerner, A. J., Su, M., Elizarov, A. M., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130098 · Cited by 683
Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease
Leon, R. M., García, A. G., & Marco, J. L. (2011) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 447
New Acetylcholinesterase Inhibitors for Alzheimer's Disease
Mehta, M., Adem, A., & Sabbagh, M. N. (2011) · International Journal of Alzheimer s Disease · doi:10.1155/2012/728983 · Cited by 436
Self-citation
The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease
McManus, M. J., Murphy, M. P., & Franklin, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0552-11.2011 · Cited by 432
Exercise and Alzheimer’s disease biomarkers in cognitively normal older adults
Liang, K. Y., Mintun, M. A., Fagan, A. M., Goate, A. M., Bugg, J. M., Holtzman, D. M., Morris, J. C., & Head, D. (2010) · Annals of Neurology · doi:10.1002/ana.22096 · Cited by 340
Monoaminergic neuropathology in Alzheimer’s disease
Šimić, G., Leko, M. B., Wray, S., Harrington, C. R., Delalle, I., Milošević, N. J., Bažadona, D., Buée, L., de Silva, R., Giovanni, G. D., et al. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.001 · Cited by 297
Physical Exercise Protects Against Alzheimer's Disease in 3xTg-AD Mice
García‐Mesa, Y., López, J. C., Giménez‐Llort, L., Revilla, S., Guerra, R., Gruart, A., LaFerla, F. M., Cristòfol, R. M., Delgado-Garcia, J. M., & Sanfeliu, C. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101635 · Cited by 258
Green Tea Epigallocatechin-3-Gallate (EGCG) and Other Flavonoids Reduce Alzheimer's Amyloid-Induced Mitochondrial Dysfunction
Dragicevic, N., Smith, A., Lin, X., Yuan, F., Copes, N., Delic, V., Tan, J., Cao, C., Shytle, R. D., & Bradshaw, P. C. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101629 · Cited by 192
The Role of Phytochemicals in the Treatment and Prevention of Dementia
Howes, M. R., & Perry, E. K. (2011) · Drugs & Aging · doi:10.2165/11591310-000000000-00000 · Cited by 187
Adherence to a Mediterranean diet and risk of incident cognitive impairment
Tsivgoulis, G. K., Judd, S. E., Letter, A. J., Alexandrov, A. V., Howard, G., Nahab, F. B., Unverzagt, F. W., Moy, C. S., Howard, V. J., D, B. M. K. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182904f69 · Cited by 190
The GABAergic system as a therapeutic target for Alzheimer's disease
Guzmán, B. C., Vinnakota, C., Govindpani, K., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14345 · Cited by 172
GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia
Xu, M., & Wong, A. H. C. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.172 · Cited by 168
Apomorphine treatment in Alzheimer mice promoting amyloid‐β degradation
Himeno, E., Ohyagi, Y., Ma, L., Nakamura, N., Miyoshi, K., Sakae, N., Motomura, K., Soejima, N., Yamasaki, R., Hashimoto, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22319 · Cited by 155
Role of GABAB receptors in learning and memory and neurological disorders
Heaney, C. F., & Kinney, J. W. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.01.007 · Cited by 162
From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases
Cassano, T., Villani, R., Pace, L., Carbone, A., Bukke, V. N., Orkisz, S., Avolio, C., & Serviddio, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00124 · Cited by 156
Neuroprotective therapeutics for Alzheimer's disease: progress and prospects
Palmer, A. M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.007 · Cited by 136
The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects
Sleegers, K., Lambert, J.-C., Bertram, L., Cruts, M., Amouyel, P., & Van Broeckhoven, C. (2010) · Trends in Genetics · doi:10.1016/j.tig.2009.12.004 · Cited by 129
Late onset Alzheimer’s disease in older people
Işık, A. T. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s11718 · Cited by 132
The role of serotonin in cognitive function: evidence from recent studies and implications for understanding depression
Cowen, P. J., & Sherwood, A. C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113482531 · Cited by 125
Pharmacological Treatment of Alzheimer Disease
Massoud, F., & Léger, G. C. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105601003 · Cited by 130
Current therapeutic targets for the treatment of Alzheimer’s disease
Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 123
One-Carbon Metabolism and Alzheimers Disease: Focus on Epigenetics
Coppedè, F. (2010) · Current Genomics · doi:10.2174/138920210791233090 · Cited by 118
Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease
Bulic, B., Pickhardt, M., & Mandelkow�, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017317 · Cited by 119
Novel insights for the treatment of Alzheimer's disease
Kurz, A., & Perneczky, R. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.018 · Cited by 115
α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer’s Disease
Toyohara, J., & Hashimoto, K. (2010) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501004010037 · Cited by 109
GABAergic neurotransmission and new strategies of neuromodulation to compensate synaptic dysfunction in early stages of Alzheimer’s disease
Nava-Mesa, M. O., Jiménez‐Díaz, L., Yajeya, J., & Navarro‐López, J. D. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00167 · Cited by 106
Faster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 104
Serotonergic Therapies for Cognitive Symptoms in Alzheimer’s Disease: Rationale and Current Status
Ramírez, M. J., Lai, M. K. P., Tordera, R. M., & Francis, P. T. (2014) · Drugs · doi:10.1007/s40265-014-0217-5 · Cited by 94
Gender-Specific Neuroimmunoendocrine Response to Treadmill Exercise in 3xTg-AD Mice
Giménez‐Llort, L., García, Y., Buccieri, K., Revilla, S., Sunol, C. E., Cristòfol, R. M., & Sanfeliu, C. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/128354 · Cited by 95
Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease
Satlin, A., Wang, J., Logovinsky, V., Berry, S. M., Swanson, C. J., Dhadda, S., & Berry, D. A. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.01.001 · Cited by 89
Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer’s disease
Ye, M., Chung, H., Lee, C., Yoon, M. S., Yu, A., Kim, J. S., Hwang, D., Shim, I., & Bae, H. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0476-z · Cited by 97
Inhibition of acetylcholinesterase by two genistein derivatives: kinetic analysis, molecular docking and molecular dynamics simulation
Fang, J., Wu, P., Yang, R., Gao, L., Li, C., Wang, D., Wu, S., Liu, A., & Du, G. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.10.002 · Cited by 89
Alzheimer's disease and age-related memory decline (preclinical)
Terry, A. V., Callahan, P. M., Hall, B. J., & Webster, S. J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.002 · Cited by 86
Oxidative Stress, Mitochondrial Abnormalities and Proteins Deposition: Multitarget Approaches in Alzheimer's Disease
Giulia, N., Sestito, S., Digiacomo, M., & Rapposelli, S. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666170607114232 · Cited by 86
Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer’s disease (AD)
Lukiw, W. J. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.672559 · Cited by 76
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer’s disease
Tasso, B., Catto, M., Nicolotti, O., Novelli, F., Tonelli, M., Giangreco, I., Pisani, L., Sparatore, A., Boido, V., Carotti, A., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.02.071 · Cited by 75
Preclinical AD Workgroup staging: Pathological correlates and potential challenges
Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., Stiles, N., Mendiondo, M. S., Smith, C. D., Van Eldik, L. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.018 · Cited by 71
Protective Effects of Baicalin on Aβ1–42-Induced Learning and Memory Deficit, Oxidative Stress, and Apoptosis in Rat
Haitao, D., Wang, H., Zhao, Y., Sun, D., & Xu, Z. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0156-z · Cited by 69
The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia
Beinat, C., Banister, S. D., Herrera, M., Law, V., & Kassiou, M. (2015) · CNS Drugs · doi:10.1007/s40263-015-0260-0 · Cited by 68
Novel Anti-Alzheimer’s Therapeutic Molecules Targeting Amyloid Precursor Protein Processing
Uddin, M. S., Kabir, M. T., Jeandet, P., Mathew, B., Ashraf, G. M., Perveen, A., Bin-Jumah, M. N., Mousa, S. A., & Abdel‐Daim, M. M. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/7039138 · Cited by 67
Design, Synthesis, and Biological Evaluation of Coumarin Derivatives Tethered to an Edrophonium‐like Fragment as Highly Potent and Selective Dual Binding Site Acetylcholinesterase Inhibitors
Pisani, L., Catto, M., Giangreco, I., Leonetti, F., Nicolotti, O., Stefanachi, A., Cellamare, S., & Carotti, A. (2010) · ChemMedChem · doi:10.1002/cmdc.201000210 · Cited by 64
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 61
New Therapeutic Targets in Alzheimer's Disease
Coman, H. G., & Nemeş, B. (2017) · International journal of gerontology · doi:10.1016/j.ijge.2016.07.003 · Cited by 63
“Clicked” Bivalent Ligands Containing Curcumin and Cholesterol As Multifunctional Aβ Oligomerization Inhibitors: Design, Synthesis, and Biological Characterization
Lenhart, J. A., Ling Zhi, X. I. A. O., Gandhi, R., Guo, T. L., Gerk, P. M., Brunzell, D. H., & Zhang, S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100601q · Cited by 60
Rethinking Alzheimer's Disease Therapy: Are Mitochondria the Key?
Ankarcrona, M., Mangialasche, F., & Winblad, B. G. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100327 · Cited by 60
Bapineuzumab: Anti-β-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer‘s Disease
Panza, F., Frisardi, V., Imbimbo, B. P., D’Onofrio, G., Pietrarossa, G., Seripa, D., Pilotto, A., & Solfrizzi, V. (2010) · Immunotherapy · doi:10.2217/imt.10.80 · Cited by 59
Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative
Grill, J. D., Di, L., Lu, P. H., Lee, C., Ringman, J., Apostolova, L. G., Chow, N., Kohannim, O., Cummings, J. L., Thompson, P. M., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.006 · Cited by 58
Neurotrophin receptor agonists and antagonists as therapeutic agents: An evolving paradigm
Josephy-Hernandez, S., Jmaeff, S., Pirvulescu, I., Aboulkassim, T., & Saragovi, H. U. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.004 · Cited by 54
Multiple Targeting Approaches on Histamine H3 Receptor Antagonists
Khanfar, M. A., Affini, A., Lutsenko, K., Nikolic, K. M., Butini, S., & Stark, H. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00201 · Cited by 53
Blockade of GABA(B) receptors completely reverses age-related learning impairment
LaSarge, C. L., Bañuelos, C., Mayse, J. D., & Bizon, J. L. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.08.055 · Cited by 52
Amyloid-β imaging with PET in Alzheimer’s disease: is it feasible with current radiotracers and technologies?
Moghbel, M. C., Saboury, B., Basu, S. K., Metzler, S. D., Torigian, D. A., Långström, B., & Alavi, A. A. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1960-4 · Cited by 53
Fermented milk of Lactobacillus helveticus IDCC3801 reduces beta-amyloid and attenuates memory deficit
Yeon, S.-W., You, Y., Kwon, H.-S., Yang, E. H., Ryu, J.-S., Kang, B. H., & Kang, J. (2010) · Journal of Functional Foods · doi:10.1016/j.jff.2010.04.002 · Cited by 51
Diet-Microbiota-Brain Axis in Alzheimer’s Disease
Kincaid, H. J., Nagpal, R., & Yadav, H. (2021) · Annals of Nutrition and Metabolism · doi:10.1159/000515700 · Cited by 51
GABA Attenuates Amyloid Toxicity by Downregulating its Endocytosis and Improves Cognitive Impairment
Sun, X., Meng, X., Zhang, J., Li, Y., Wang, L., Qin, X., Sui, N., & Zhang, Y. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120535 · Cited by 44
Novel therapeutics for Alzheimer's disease: an update.
Bonda, D., Lee, H. P., Lee, H., Friedlich, A. L., Perry, G. L., Zhu, X., & Smith, M. A. (2010) · PubMed · Cited by 41
The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model
Spilman, P. R., Descamps, O., Gorostiza, O. F., Peters-Libeu, C. A., Poksay, K. S., Matalis, A., Campagna, J. J., Patent, A., Rao, R. V., John, V., et al. (2014) · Brain Research · doi:10.1016/j.brainres.2013.12.029 · Cited by 44
The Binding Mechanisms and Inhibitory Effect of Intravenous Anesthetics on AChE In Vitro and In Vivo: Kinetic Analysis and Molecular Docking
Işık, M. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02852-y · Cited by 41
Design, synthesis and biological evaluation of benzo[e][1,2,4]triazin-7(1H)-one and [1,2,4]-triazino[5,6,1-jk]carbazol-6-one derivatives as dual inhibitors of beta-amyloid aggregation and acetyl/butyryl cholinesterase
Catto, M., Berezin, A. A., Re, D. L., Loizou, G., Demetriades, M., Stradis, A. D., Campagna, F., Koutentis, P. A., & Carotti, A. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.10.003 · Cited by 41
Alpha-7 Nicotinic Receptors in Nervous System Disorders: From Function to Therapeutic Perspectives
Jaco, A. D., Bernardini, L., Rosati, J. D., & Tata, A. M. (2016) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1871524916666160729111446 · Cited by 40
Staging anti-inflammatory therapy in Alzheimer’s disease
Lichtenstein, M. P. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00142 · Cited by 39
Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform
Kolaj, I., Liyanage, S. I., & Weaver, D. F. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.08.001 · Cited by 39
GABAB receptor GTP-binding is decreased in the prefrontal cortex but not the hippocampus of aged rats
McQuail, J. A., Bañuelos, C., LaSarge, C. L., Nicolle, M. M., & Bizon, J. L. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.011 · Cited by 38
Modulating Nitric Oxide Signaling in the Cns for Alzheimer’s Disease Therapy
Zhihui, Q. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.111 · Cited by 37
Therapeutic efficacy of stemazole in a beta-amyloid injection rat model of Alzheimer's disease
Han, M., Liu, Y. M., Tan, Q., Zhang, B., Wang, W., Liu, J., Zhang, X., Wang, Y., & Zhang, J. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.01.065 · Cited by 33
Dual Histamine H3R/Serotonin 5-HT4R Ligands with Antiamnesic Properties: Pharmacophore-Based Virtual Screening and Polypharmacology
Lepailleur, A., Fréret, T., Lemaître, S., Boulouard, M., Dauphin, F., Hinschberger, A., Dulin, F., Lesnard, A., Bureau, R., & Rault, S. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500157n · Cited by 33
Frontiers in Alzheimer’s disease therapeutics
Stone, J. G., Casadesús, G., Rothenberg, K. G., Siedlak, S. L., Wang, X., Zhu, X., Perry, G. L., Castellani, R. J., & Smith, M. A. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310382817 · Cited by 32
Synopsis of recent synthetic methods and biological applications of phosphinic acid derivatives
Abdou, M. M. (2020) · Tetrahedron · doi:10.1016/j.tet.2020.131251 · Cited by 32
Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.
Sabbagh, M. N., & Shill, H. A. (2010) · PubMed · Cited by 32
Self-citation
Unfolded p53 in Blood as a Predictive Signature Signature of the Transition from Mild Cognitive Impairment to Alzheimer's Disease
Lanni, C., Racchi, M., Stanga, S., Mazzini, G., Ranzenigo, A., Polotti, R., Memo, M., Govoni, S. M., & Uberti, D. L. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1347 · Cited by 29
Promising Therapies for Alzheimer';s Disease
Confaloni, A., Tosto, G., & Tata, A. M. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160215154218 · Cited by 29
Current Therapies and New Strategies for the Management of Alzheimer’s Disease
Aderinwale, O. G., Ernst, H. W., & Mousa, S. A. (2010) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317510372372 · Cited by 27
Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT
Declercq, L., Vandenberghe, R. R., Laere, K. V., Verbruggen, A., & Bormans, G. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00088 · Cited by 27
Kinetics and Molecular Docking Study of an Anti-diabetic Drug Glimepiride as Acetylcholinesterase Inhibitor: Implication for Alzheimer’s Disease-Diabetes Dual Therapy
Rizvi, S. M. D., Shaikh, S., Naaz, D., Shakil, S., Ahmad, A., Haneef, M., & Abuzenadah, A. M. (2016) · Neurochemical Research · doi:10.1007/s11064-016-1859-3 · Cited by 26
The α7 nAChR Selective Agonists as Drug Candidates for Alzheimer’s Disease
Fan, H., Gu, R., & Wei, D. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-9245-5_21 · Cited by 24
Standardized Herbal Formula PM012 Decreases Cognitive Impairment and Promotes Neurogenesis in the 3xTg AD Mouse Model of Alzheimer’s Disease
Ye, M., Chung, H., An, Y. H., Lim, S.-J., Choi, W., Yu, A., Kim, J. S., Kang, M., Cho, S., Shim, I., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9458-x · Cited by 22
Pharmacotherapy for dementia
Youn, H., & Jeong, H. (2018) · Journal of Korean Medical Association · doi:10.5124/jkma.2018.61.12.758 · Cited by 23
THE CONNECTION BETWEEN DIFFERENT NEUROTRANSMITTERS INVOLVED IN COGNITIVE PROCESSES
Handra, C. M. (2019) · FARMACIA · doi:10.31925/farmacia.2019.2.1 · Cited by 22
Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM‐Elderly Project
Franchi, C., Lucca, U., Tettamanti, M., Riva, E., Fortino, I., Bortolotti, A., Merlino, L. G., Pasina, L., & Nobili, A. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2124 · Cited by 23
Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease
Han, S.-H., & Mook‐Jung, I. (2014) · Journal of Korean Medical Science · doi:10.3346/jkms.2014.29.7.893 · Cited by 23
Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration
Dar, K. B., Bhat, A. H., Amin, S., Reshi, B. A., Zargar, M. A., Masood, A., & Ganie, S. A. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00741-0 · Cited by 23
Bivalent Ligands Targeting Multiple Pathological Factors Involved in Alzheimer's Disease
Liu, K., Gandhi, R., Chen, J., & Zhang, S. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300229y · Cited by 21
Alzheimer's Disease
Mandell, A. M., & Green, R. C. (2011) · Wiley eBooks · doi:10.1002/9781444344110.ch1 · Cited by 22
Physicians and caregivers: Ready and waiting for increased participation in clinical research
Jones, R. W., Andrieu, S., Knox, S., & Mackell, J. A. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0269-5 · Cited by 20
Cholinesterase inhibitory activity of tinosporide and 8-hydroxytinosporide isolated from Tinospora cordifolia: In vitro and in silico studies targeting management of Alzheimer’s disease
Adib, M., Islam, R., Ahsan, M., Rahman, A., Hossain, M., Rahman, M. M., Alshehri, S. M., Kazi, M., & Mazid, M. A. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.03.063 · Cited by 19
Research and development of anti-Alzheimer’s drugs: an analysis based on technology flows measured by patent citations
Xu, J., Kong, X., Qiu, L., Geng, X., Yuanjia, H., & Wang, Y. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.915943 · Cited by 19
Assessing Neuroprotective Agents for Aβ-Induced Neurotoxicity
Forest, K. H., & Nichols, R. A. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.05.013 · Cited by 19
α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease~!2009-10-15~!2009-10-30~!2010-05-27~!
Toyohara, J., & Hashimoto, K. (2010) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501004020037 · Cited by 18
A plant cell-based system that predicts aβ42 misfolding: Potential as a drug discovery tool for Alzheimer's disease
Zhao, T., Zeng, Y., & Kermode, A. R. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2012.08.010 · Cited by 17
Rapid Cytotoxicity Screening Platform for Amyloid Inhibitors Using a Membrane-Potential Sensitive Fluorescent Probe
Kim, J., Sasaki, Y., Yoshida, W., Kobayashi, N., Veloso, A. J., Kerman, K., Ikebukuro, K., & Sode, K. (2012) · Analytical Chemistry · doi:10.1021/ac302442q · Cited by 18
Down syndrome: A curative prospect?
Rondal, J. A. (2020) · AIMS neuroscience · doi:10.3934/neuroscience.2020012 · Cited by 14
Study design considerations: Conducting global clinical trials in early Alzheimer's disease
Schindler, R. J. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0071-4 · Cited by 16
Development of a dual nanocarrier system as a potential stratagem against amyloid-induced toxicity
Kumaraswamy, P., Sethuraman, S., & Krishnan, U. M. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.912211 · Cited by 14
Role of Acetylcholinesterase Inhibitors and Alzheimer Disease
Saify, Z. S., & Sultana, N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50007-6 · Cited by 14
ALZHEIMER DISEASE UPDATE
Matthews, B. R. (2010) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000368210.41093.4e · Cited by 15
Targeting the GABAB Receptor for the Treatment of Depression and Anxiety Disorders
Felice, D., O’Leary, O. F., & Cryan, J. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-46044-4_12 · Cited by 13
Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia
Luo, J., Lee, S., VandeVrede, L. A., Qin, Z., Piyankarage, S. C., Tavassoli, E., Asghodom, R. T., Aissa, M. B., Fà, M., Arancio, O., et al. (2015) · BMC Neuroscience · doi:10.1186/s12868-015-0208-9 · Cited by 12
Toxicological scoring of Alzheimer’s disease drug huperzine in a guinea pig model
Pohanka, M., Zemek, F., Banďouchová, H., & Pikula, J. (2011) · Toxicology Mechanisms and Methods · doi:10.3109/15376516.2011.635320 · Cited by 12
Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects
NEWHOUSE, P. A. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty189 · Cited by 11

Authors: Sabbagh, M. N.
Affiliations: Banner Sun Health Research Institute (US)
Corresponding author: Sabbagh, Marwan N.
ORCID: Sabbagh, Marwan N.
Venue: The American journal of geriatric pharmacotherapy
Publisher: Elsevier BV
Published: 2009-06
Volume: 7
Issue: 3
Pages: 167-185
ISSN: 1543-5946 (ISSN-L)
DOI: 10.1016/j.amjopharm.2009.06.003
PMC: PMC2948028
OpenAlex: W2004845278
Cited by: 147
References: 95
Citations by year: 2026: 2 · 2025: 1 · 2024: 1 · 2023: 1 · 2021: 5 · 2020: 8 · 2019: 6 · 2018: 5 · 2017: 3 · 2016: 12 · 2015: 6 · 2014: 15 · 2013: 8 · 2012: 13
FWCI: 2.74
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The American Journal of Geriatric Pharmacotherapy (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Pfizer
National Institute for Health and Care Research
Eisai
National Health Research Institutes
National Institutes of Health
National Institute on Aging (P30AG019610)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, drug development, pharmacotherapy, clinical trials, dementia prevention, Ginkgo biloba, nonsteroidal anti-inflammatory drugs, phenserine, statins, tramiprosate, dimebon, huperzine A, intravenous immunoglobulin, methylene blue
MeSH terms: Alzheimer Disease, Animals, Humans, Drug Design, Randomized Controlled Trials as Topic, Drug Delivery Systems, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Drug development for Alzheimer's disease: Where are we now and where are we headed?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks